CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Latima SIA is developing Rigvir®, a non-pathogenic virus-based treatment for melanoma, aiming to improve cancer therapy effectiveness and accessibility. The project focuses on conducting a feasibility study to support future clinical trials for regulatory approval in the European Union.
Cancer is one of the most dangerous life-threatening disorders for humanity of which melanoma is considered to be one ofthe most dangerous and aggressive.
There are a number of therapies available to treat melanoma.
However, thesetreatments are generally marginally effective and very expensive.Latima SIA develops and produces Rigvir® for virotherapy.
Rigvir® is a unique anti-cancer medicine using non-pathogenicvirus.
It has been demonstrated to be very effective in treating various cancers, and…
SABIEDRIBA AR IEROBEZOTU ATBILDIBU LATIMA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
